Skip to main content
DERM
NASDAQ Life Sciences

Journey Medical Q3 Revenue Rises 8% as Emrosi Sales Jump 84%

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.354
Mkt Cap
$123.905M
52W Low
$4.25
52W High
$9.555
52W Position info
2.4% above low
Off High info
54% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

DERM is trading near its 52-week low of $4.25 (2.4% above the low).

Summary

Journey Medical posted Q3 2026 total revenue of $19.0 million, up 8% from $17.6 million a year ago, though the result missed estimates, with its lead rosacea drug Emrosi generating $9.0 million, an 84% year-over-year increase. Gross margin improved to 69% from 67%, and the GAAP net loss narrowed to $1.3 million, or $(0.05) per share, from a $2.3 million loss a year earlier. The company reported positive EBITDA and Adjusted EBITDA of $3.5 million for the quarter, a swing from $1.4 million a year ago, though SG&A included a one-time $1.7 million vendor dispute settlement. Cash stood at $22.3 million at September 30, down from $24.1 million at year-end 2025, and the balance sheet carries a $7.5 million short-term term loan plus $18.1 million long-term. This follows the Q2 10-Q filed August 12 that flagged going concern and debt repayments starting in 2027; the improving Emrosi trend and positive EBITDA are the key data points against that backdrop. Fortress Biotech (FBIO) is the founder and controlling shareholder of Journey Medical, so the read-through is indirect for FBIO. Management's conference call is today at 4:30 p.m. ET.

At the time of this announcement, DERM was trading at $4.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.9M. The 52-week trading range was $4.25 to $9.56. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

DERM - Latest Insights

DERM
Nov 12, 2026, 4:35 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.90
Real-time Price: $4.42 info
Change: -$0.480 (-10%) info
Market Cap: $123.905M info
DERM
Aug 12, 2026, 4:40 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.99
Real-time Price: $4.42 info
Change: -$2.57 (-37%) info
Market Cap: $123.905M info
DERM
Aug 12, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.61
Real-time Price: $4.42 info
Change: -$2.19 (-33%) info
Market Cap: $123.905M info
DERM
Aug 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.61
Real-time Price: $4.42 info
Change: -$2.19 (-33%) info
Market Cap: $123.905M info
DERM
May 13, 2026, 4:33 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.57
Real-time Price: $4.42 info
Change: -$1.15 (-21%) info
Market Cap: $123.905M info